Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening immune dysregulation disease. Patients with inflammatory bowel disease (IBD) can become profoundly immunocompromised due to immunosuppressive therapy, hence increasing the risk of viral infections that can trigger HLH. However, data on the association between IBD and HLH remains limited. We used data from the National Inpatient Sample (2012–2019) utilizing International Classification of Diseases (ICD)-9 or ICD-10 codes to identify individuals with IBD, either Crohn’s disease (CD) or ulcerative colitis (UC), and HLH. The primary outcome was to compare the prevalence of HLH among patients with IBD with those without IBD. Secondary outcomes included in-hospital mortality, mean hospital length of stay, and description of HLH-associated triggers in IBD patients. A total of 513,322 hospitalizations included a diagnosis of IBD, 188,297 had UC and 325,025 had CD. Compared to the general population, patients with IBD were older (median age of 52 vs. 49 years, p < 0.05), more likely to be male, and of Asian/Pacific Islander descent, and had a higher median household income. There was also a higher prevalence of liver disease, autoimmune diseases, tobacco abuse, and hypothyroidism (all had p-value of < 0.001) in IBD patients. There were 94 hospitalizations identified with a diagnosis of HLH in IBD patients. Compared to patients without IBD, patients with IBD had increased odds of developing HLH (0.02% vs 0.01%, p-value < 0.001). After adjusting for various demographic characteristics, co-morbidities, and HLH-related conditions, IBD was an independent predictor for developing HLH (adjusted OR, 2.3; 95% CI, 1.847–2.866, p-value of < 0.001). There was no statistical difference between CD and UC in the odds of developing HLH. Compared to IBD patients without HLH, patients with IBD and HLH had a lower mean age at diagnosis (38 vs 52, p-value of < 0.001), higher in-hospital mortality (14.9% vs 1.5%, p-value of < 0.001), and longer mean hospital length of stay (days) (17 vs 5.4, p-value of < 0.001). Prevalence of different HLH-associated illnesses was identified in HLH patient’s discharge data. Lymphoma was the most common associated malignancy (18.1%) and cytomegalovirus infection was the most common associated infection (16.0%). Our population-based study suggests that IBD is independently associated with developing HLH. Early recognition of IBD patients presenting with features suggestive of HLH is warranted to aide early diagnosis and aggressive treatment.
Similar content being viewed by others
Data availability
The data used in this study is available in the national inpatient sample at www.hcup-us.ahrq.gov. All data generated or analyzed during this study are included in this published article.
References
Griffin G, Shenoi S, Hughes GC (2020) Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol 34(4):101515
Parikh SA et al (2014) Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89(4):484–492
Rouphael NG et al (2007) Infections associated with haemophagocytic syndrome. Lancet Infect Dis 7(12):814–822
Henter JI et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131
La Rosée P et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood, J Am Soc Hematol 133(23):2465–2477
Coburn ES et al (2021) Hemophagocytic lymphohistiocytosis occurring in inflammatory bowel disease: systematic review. Dig Dis Sci 66(3):843–854
Sairenji T, Collins KL, Evans DV (2017) An update on inflammatory bowel disease. Prim Care 44(4):673–692
Jordan MB et al (2019) Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer 66(11):e27929
Brambilla B et al (2020) Hemophagocytic lymphohistiocytosis and inflammatory bowel disease: case report and systematic review. Inflamm Intest Dis 5(2):49–58
Li Y et al (2015) Haemophagocytic lymphohistiocytosis in inflammatory bowel disease with virus infection. Gastroenterol Rev/Przegląd Gastroenterol 10(2):78–82
Ramos-Casals M et al (2014) Adult haemophagocytic syndrome. Lancet 383(9927):1503–1516
Bhatt NS, Oshrine B, An Talano J (2019) Hemophagocytic lymphohistiocytosis in adults. Leuk Lymphoma 60(1):19–28
Bedi PS et al (2018) Demographics, treatment outcomes and resource utilization among patients hospitalized with adult onset hemophagocytic lymphohistiocytosis (HLH): a nationwide analysis. Blood 132(Supplement 1):4784–4784
Tong QJ et al (2019) An elusive diagnosis: case reports of secondary hemophagocytic lymphohistiocytosis and review of current literature. Cureus 11(4):e4548
Toruner M et al (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134(4):929–936
Hendler SA et al (2020) Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide. Int J Colorectal Dis 35(5):897–903
Goetgebuer RL, et al (2022) The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists. Scand J Gastroenterol, p. 1–6
Römkens TE et al (2016) Cytomegalovirus in inflammatory bowel disease: a systematic review. World J Gastroenterol 22(3):1321–1330
Rolsdorph L et al (2022) Concomitant hemophagocytic lymphohistiocytosis and cytomegalovirus disease: a case based systemic review. Front Med (Lausanne) 9:819465
Author information
Authors and Affiliations
Contributions
AM contributed to the study conception, design, data analysis, and review of manuscript. AA contributed to design and data analysis. The first draft of the manuscript was written by AK, MM, and AS. MM and BE contributed to manuscript editing and visuals. TM contributed to critical review of the final manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
This study was based on the use of de-identified public data from the national inpatient sample database and did not involve interaction with human subjects or the use of personal identifying information.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mahmoud, A.A., Abdelhay, A., Khamis, A. et al. Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis. Ann Hematol 102, 1705–1711 (2023). https://doi.org/10.1007/s00277-023-05223-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05223-4